Sanofi’s plans for rilzabrutinib continue apace with positive mid-stage data in IgG4-related disease ahead of a potential US approval in the summer for the potential ‘pipeline-in-a-product’ in immune thrombocytopenia (ITP).
Key Takeaways
- Treatment with rilzabrutinib led to a considerable reduction in disease flares in patients with active IgG4-related disease.
The French drugmaker has presented new data at the European Alliance of Associations for Rheumatology (EULAR) congress in Barcelona, Spain,...
Welcome to Scrip
Create an account to read this article
Already a subscriber?